| Name | Title | Contact Details |
|---|
Founded by Chief Executive Officer Sam Solakyan, Global Holdings, Inc. has excelled in its journey in becoming leaders in each of the industries it has a presence in. Their main responsibility lies in providing their clients with the most premiere level of service. More than just your typical holdings group, Global is a multifaceted company with financial assets and ownership in the radiology, pharmaceuticals, and medical billing and collections industries. Instead of merely buying and selling companies like other holdings groups, Global searches for the less desirable companies with hidden potential and applies its knowledge and expertise in the management field and aids in the recreation of a company that once was not.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
The American Association for Thoracic Surgery is an international organization of over 1,500 of the worlds foremost cardiothoracic surgeons representing 41 countries. The mission of the AATS is to promote scholarship, innovation, and leadership in tho...
Centerstone is a not-for-profit health system providing mental health and substance use disorder treatments. Services are available nationally through the operation of outpatient clinics, residential programs, the use of telehealth and an inpatient hospital. Centerstone also features specialized programs for the military community, therapeutic foster care, children`s services and employee assistance programs. Centerstone`s Research Institute provides guidance through research and technology, leveraging the best practices for use in all our communities. Centerstone`s Foundation secures philanthropic resources to support the work and mission of delivering care that changes people`s lives.
Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned subsidiary, Par Pharmaceutical, Inc., is in the business of developing, manufacturing and distributing generic and branded drugs in the United States.